Middle East and Asia Pacific Cell and Gene Therapy Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others), by Technology (Lentiviral Vector, Plasmid DNA, and AAV), and by Region (Middle East and Asia Pacific), is estimated to be valued at US$ 2,616.8 million in 2021 and is expected to exhibit a CAGR of 17.3% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
The increasing Robust Pipeline of cell and gene therapy is the major factor that is expected to drive growth of the Middle East and Asia Pacific cell and gene therapy market. Cell and gene therapy is a leading field in medical science, which promises new treatment development for patients suffering from various diseases such as oncology, immunology and others. For instance, Adeno-associated AAV2 vectors carrying therapeutic gene (RPE65) intra-retinal injection lead to improve the vision of individuals suffering from Leber’s Congenital Amaurosis an eye disorder. Several clinical trials are being conducted on cell and gene therapy that are focused on potential diseases. There is an increase in investments in drug development and commercialization of these therapies, in order to meet significant medical needs. Genetic markers are associated with complex diseases, therefore it is important to study the genetic information and its clinical application in designing clinical trials and cell and gene therapy product manufacturing.
According to the data published by the Journal of Gene Medicine, in 2017, an estimated 2,600 gene therapy clinical trials are ongoing, have been completed, or have been approved in 36 countries. Countries where the trials were conducted include Australia, China, France, Japan, Switzerland, the Netherlands, and others. Moreover, diseases targeted by cell and gene therapies include cardiovascular diseases, cancer, inflammatory and infectious diseases, Hemophilia A and B, severe combined immunodeficiency (SCID), ocular diseases, neurological diseases, and others.
Middle East and Asia Pacific Cell and Gene Therapy Market – COVID-19 Impact
Imposing strict lockdowns in many countries globally have adversely impacted the economy of the healthcare sector.
This lockdown resulted in the closure of industrial establishments, except for the manufacturing of essential commodities and disruption in supply chain of the products. Thus, COVID-19 pandemic has affected the economy in three main ways: by directly affecting the production and demand, by creating disruptions in distribution channels, and by its financial impact on firms and financial markets.
Supply chain and manufacturing activities in the Middle East and the Asia Pacific regions have been disrupted due to lockdown.
Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources, which are required to ensure safety in hospitals and provide treatment to patients with other diseases, which has also impacted the market negatively. One of the biggest challenges is supplying the raw materials required to manufacture drugs due to irregularities in the transportation system. Additionally, due to the increasing number of patients suffering from COVID-19 and other life-threatening illnesses, product distributors are witnessing increasing demand for raw materials used for manufacturing cell and gene therapy products from retailers.
Browse 20 Market Data Tables and 26 Figures spread through 425 Pages and in-depth TOC on “Middle East and Asia Pacific Cell and Gene Therapy Market”- Middle East and Asia Pacific Forecast to 2028, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others), by Technology (Lentiviral Vector, Plasmid DNA, and AAV), and by Region (Middle East and Asia Pacific)
To know the latest trends and insights prevalent in the Middle East and Asia Pacific Cell and Gene Therapy Market, click the link below:
Factors such as increasing approval of gene therapy by regulatory authorities for the treatment of adolescents and adults with transfusion-dependent β-thalassemia (TDT) and a non-β0/β0 genotype are expected to drive the market growth.
For instance, in October 2018, bluebird bio, Inc., a biotechnology company received European Medicines Agency (EMA) marketing authorization application (MAA) for its investigational LentiGlobin gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassemia (TDT) and a non-β0/β0 genotype.
Key Takeaways of the Middle East and Asia Pacific Cell and Gene Therapy Market:
- Middle East and Asia Pacific cell and gene therapy market is expected to exhibit a CAGR of 17.3% over the forecast period, owing to increasing adoption of inorganic growth strategies by market players such as partnerships and collaborations. For instance, in February 2021, SIRION Biotech, a company that develops optimized viral vectors for gene and cell therapy, announced collaboration with Sanofi S.A. pharmaceutical industry company to innovate gene therapy treatments with improved adeno-associated virus capsids.
- Among therapy type, cell therapy segment is expected to account for the largest market share in 2021, owing to researchers focusing on Covid-19 treatment with stem cells. For instance, according to the publication in the United Arab Emirates Government portal, a team of doctors and researchers at Abu Dhabi Stem Cell Center-ADSCC in UAE successfully used stem cells to treat COVID-19 infection
Key players operating in the Middle East and Asia Pacific cell and gene therapy market include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bluebird Bio, Inc. (Celgene Corporation), Gene biotherapeutics, Sibiono GeneTech Co. Ltd., Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Biogen INC., Organogenesis, Inc., JCR Pharmaceuticals Co. Ltd, uniQure N.V., WuxiAppTec, Lonza, and Immuneel Therapeutics Pvt Ltd.
